Adma Biologics reported $51.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Adma Biologics USD 51.01M 8.21M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Takeda JPY 168.82B 479.89B Dec/2025